Table 2 Treatment and outcomes at discharge of the study subjects.
ES group (n = 66) | Non-ES group (n = 2903) | P value | |
|---|---|---|---|
Intravenous alteplase | 9 (14) | 421 (15) | 1.000 |
Endovascular therapy | 5 (10) | 183 (7.3) | 0.402 |
Edaravone | 40 (61) | 1873 (65) | 0.517 |
Statin treatment | 20 (30) | 1603 (55) | <0.001 |
Statin use before index-stroke | 11 (17) | 764 (26) | 0.089 |
Statin use in acute phase | 19 (29) | 1511 (52) | <0.001 |
Statin treatment after acute phase | 22 (33) | 1673 (58) | <0.001 |
mRS scores at discharge | 4 [3–5] | 2 [1–4] | 0.009 |
Hospital stay, day | 25.5 [18–33.5] | 18 [12–27] | <0.001 |
In hospital mortality | 3 (4.6) | 73 (2.5) | 0.238 |
